A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results

被引：4

作者：

Cunningham, D.

Wong, R. P.

D'haens, G.

Douillard, J.

Robertson, J.

Saunders, O.

Stone, M.

Van Cutsem, E.

机构：

[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[2] CancerCare Manitoba, Winnipeg, MB, Canada

[3] Imelda GI Clin Res Ctr, Bonheiden, Belgium

[4] Ctr Rene Gauducheau, St Herblain, France

[5] AstraZeneca, Macclesfield, Cheshire, England

[6] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.4028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4028

引用

页数：1